NCT02756650View on ClinicalTrials.gov

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 23, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Behcet Disease
Interventions
DRUG

Canakinumab

150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)

Trial Locations (1)

34093

Novartis Investigative Site, Istanbul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY